Mobile Units take Therapies Development on-site

Global biotech Orgenesis is collaborating with Dong-a University Hospital (South Korea) and Cure Therapeutics to utilise Orgenesis’ Mobile Processing Units and Labs (OMPULs) for point-of-care development of cell and gene therapies and immunotherapies that meet regulatory and governmental approval standards to scale through to commercialisation. Process development and validation for the therapies will be completed at the Dong-a University.

 “We are excited to expand our collaboration with Orgenesis by utilising their OMPULs onsite via a partnership with Dong-A University. The OMPULs will be placed onsite with the goal of accelerating development and commercialisation of our immunotherapies targeting cancers and infectious disease, while ensuring the highest quality control standards and reducing overall manufacturing costs,” said David Kim, CEO of Cure Therapeutics.

“We are pleased to partner with Cure Therapeutics and Dong-a University Hospital to accelerate the development and market launch of breakthrough cell and gene therapies utilising our proprietary OMPUL system,” said Vered Caplan, CEO of Orgenesis. “This latest agreement is another step in our efforts to rollout OMPULs throughout our network of leading healthcare facilities and partner companies across the US, Europe, Asia and the Middle East.”